Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population
Dennis C. Sgroi,Ivana Sestak,Jack Cuzick,Yi Zhang,Catherine A. Schnabel,Brock Schroeder,Mark G. Erlander,Anita K. Dunbier,Anita K. Dunbier,Kally Sidhu,Elena Lopez-Knowles,Paul E. Goss,Mitch Dowsett +12 more
TLDR
This prospective comparison study compared the prognostic ability of the breast-cancer index (BCI) assay, 21-gene recurrence score (Oncotype DX), and an immunohistochemical prognostic model (IHC4) for both early and late recurrence in patients with oestrogen-receptor-positive, node-negative breast cancer who took part in the Arimidex, Tamoxifen, Alone or in Combination clinical trial.Abstract:
Summary Background Biomarkers to improve the risk–benefit of extended adjuvant endocrine therapy for late recurrence in patients with oestrogen-receptor-positive breast cancer would be clinically valuable. We compared the prognostic ability of the breast-cancer index (BCI) assay, 21-gene recurrence score (Oncotype DX), and an immunohistochemical prognostic model (IHC4) for both early and late recurrence in patients with oestrogen-receptor-positive, node-negative (N0) disease who took part in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) clinical trial. Methods In this prospective comparison study, we obtained archival tumour blocks from the TransATAC tissue bank from all postmenopausal patients with oestrogen-receptor-positive breast cancer from whom the 21-gene recurrence score and IHC4 values had already been derived. We did BCI analysis in matched samples with sufficient residual RNA using two BCI models—cubic (BCI-C) and linear (BCI-L)—using previously validated cutoffs. We assessed prognostic ability of BCI for distant recurrence over 10 years (the primary endpoint) and compared it with that of the 21-gene recurrence score and IHC4. We also tested the ability of the assays to predict early (0–5 years) and late (5–10 years) distant recurrence. To assess the ability of the biomarkers to predict recurrence beyond standard clinicopathological variables, we calculated the change in the likelihood-ratio χ 2 (LR-Δχ 2 ) from Cox proportional hazards models. Findings Suitable tissue was available from 665 patients with oestrogen-receptor-positive, N0 breast cancer for BCI analysis. The primary analysis showed significant differences in risk of distant recurrence over 10 years in the categorical BCI-C risk groups (p 2 =22·69; p 2 =13·68; p=0·0002) and IHC4 was similar (HR 1·69 [95% CI 1·51–2·56]; LR-Δχ 2 =22·83; p 2 =15·42, p 2 =18·48, p 2 =29·14, p 2 =7·97, p=0·0048; 21-gene recurrence score HR 1·13 [0·82–1·56], LR-Δχ 2 =0·48, p=0·47; IHC4 HR 1·30 [0·88–1·94], LR-Δχ 2 =1·59, p=0·20). Interpretation BCI-L was the only significant prognostic test for risk of both early and late distant recurrence and identified two risk populations for each timeframe. It could help to identify patients at high risk for late distant recurrence who might benefit from extended endocrine or other therapy. Funding Avon Foundation, National Institutes of Health, Breast Cancer Foundation, US Department of Defense Breast Cancer Research Program, Susan G Komen for the Cure, Breakthrough Breast Cancer through the Mary-Jean Mitchell Green Foundation, AstraZeneca, Cancer Research UK, and the National Institute for Health Research Biomedical Research Centre at the Royal Marsden (London, UK).read more
Citations
More filters
Journal ArticleDOI
Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano,Robert Gray,D. F. Makower,Kathleen I. Pritchard,Kathy S. Albain,Daniel F. Hayes,Charles E. Geyer,Elizabeth Claire Dees,E. A. Perez,John A. Olson,John A. Olson,J. A. Zujewski,J. A. Zujewski,Tracy Lively,Sunil Badve,Tom Saphner,Lynne I. Wagner,Timothy J. Whelan,Matthew J. Ellis,Matthew J. Ellis,Soonmyung Paik,Soonmyung Paik,William C. Wood,Peter M. Ravdin,M. Keane,H. L. Gomez Moreno,Pavan S. Reddy,Timothy F. Goggins,Ingrid A. Mayer,Adam Brufsky,Deborah Toppmeyer,Virginia G. Kaklamani,JN Atkins,Jeffrey L. Berenberg,George W. Sledge,George W. Sledge +35 more
TL;DR: In this article, a prospective trial involving women with hormone-receptor-positive, human epidermal growth factor receptor type 2 (HER2)-negative, axillary node-negative breast cancer with tumors of 1.1 to 5.0 cm in the greatest dimension (or 0.6 to 1.0cm in the intermediate or high tumor grade) who met established guidelines for the consideration of adjuvant chemotherapy on the basis of clinicopathologic features.
Journal ArticleDOI
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.
Hongchao Pan,Richard Gray,Jeremy P Braybrooke,C Davies,Carolyn W. Taylor,Paul McGale,Richard Peto,Kathleen I. Pritchard,Jonas Bergh,Mitch Dowsett,Daniel F. Hayes +10 more
TL;DR: After 5 years of adjuvant endocrine therapy, breast‐cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years, with risks ranging from 10 to 41%, depending on TN status and tumor grade.
Journal ArticleDOI
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
Giuseppe Curigliano,Harold J. Burstein,Eric P. Winer,Michael Gnant,Peter Dubsky,Sibylle Loibl,Marco Colleoni,Meredith M. Regan,Martine Piccart-Gebhart,H.-J. Senn,Beat Thürlimann,Fabrice Andre,José Baselga,Jonas Bergh,Hervé Bonnefoi,Sara Y. Brucker,Fatima Cardoso,Lisa A. Carey,Eva Ciruelos,Jack Cuzick,Carsten Denkert,A. Di Leo,Bent Ejlertsen,Prudence A. Francis,Viviana Galimberti,Judy Garber,Bahadir M. Gulluoglu,Pamela J. Goodwin,Nadia Harbeck,Daniel F. Hayes,Chiun-Sheng Huang,Jens Huober,H. Khaled,Jacek Jassem,Zefei Jiang,Per Karlsson,Monica Morrow,Roberto Orecchia,Kent Osborne,Olivia Pagani,Ann H. Partridge,Kathleen I. Pritchard,Jungsil Ro,Emiel J. Th. Rutgers,Felix Sedlmayer,Vladimir Semiglazov,Zhimin Shao,I.E. Smith,Masakazu Toi,Andrew Tutt,Giuseppe Viale,Toshihiro Watanabe,Timothy J. Whelan,Bo Xu +53 more
TL;DR: The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna, Austria reviewed substantial new evidence on loco-regional and systemic therapies for early breast cancer, and recommended bisphosphonate use in postmenopausal women to prevent breast cancer recurrence.
Journal ArticleDOI
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
Lyndsay Harris,Nofisat Ismaila,Lisa M. McShane,Fabrice Andre,Deborah Collyar,Ana M. Gonzalez-Angulo,Elizabeth H. Hammond,Nicole M. Kuderer,Minetta C. Liu,Robert G. Mennel,Catherine Van Poznak,Robert C. Bast,Daniel F. Hayes +12 more
TL;DR: A literature search and prospectively defined study selection sought systematic reviews, meta-analyses, randomized controlled trials, prospective-retrospective studies, and prospective comparative observational studies published from 2006 through 2014 to provide recommendations on appropriate use of breast tumor biomarker assay results to guide decisions on adjuvant systemic therapy for women with early stage invasive breast cancer as mentioned in this paper.
Journal ArticleDOI
NCCN Guidelines® Insights Colon Cancer, Version 2.2018 Featured Updates to the NCCN Guidelines
Al B. Benson,Alan P. Venook,Mahmoud M. Al-Hawary,Lynette Cederquist,Yi Jen Chen,Kristen K. Ciombor,Stacey Cohen,Harry S. Cooper,Dustin A. Deming,Paul F. Engstrom,Ignacio Garrido-Laguna,Jean L. Grem,Axel Grothey,Howard S. Hochster,Sarah E. Hoffe,Steven C. Hunt,Ahmed Kamel,Natalie Kirilcuk,Smitha S. Krishnamurthi,Wells A. Messersmith,Jeffrey A. Meyerhardt,Eric D. Miller,Mary F. Mulcahy,James D. Murphy,Steven J. Nurkin,Leonard B. Saltz,Sunil Sharma,David Shibata,John M. Skibber,Constantinos T. Sofocleous,Elena M. Stoffel,Eden Stotsky-Himelfarb,Christopher G. Willett,Evan Wuthrick,Kristina M. Gregory,Deborah A. Freedman-Cass +35 more
TL;DR: The NCCN Colon Cancer Panel discussions for the 2018 update of the guidelines regarding risk stratification and adjuvant treatment for patients with stage III colon cancer, and treatment of BRAF V600E mutation-positive metastatic colorectal cancer with regimens containing vemurafenib are summarized.
References
More filters
Journal ArticleDOI
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
Mitch Dowsett,Torsten O. Nielsen,Roger A'Hern,John M. S. Bartlett,R. Charles Coombes,Jack Cuzick,Matthew J. Ellis,N. Lynn Henry,Judith Hugh,Tracy Lively,Lisa M. McShane,Soon Paik,Frédérique Penault-Llorca,Ljudmila Prudkin,Meredith M. Regan,Janine Salter,Christos Sotiriou,Ian E. Smith,Giuseppe Viale,Jo Anne Zujewski,Daniel F. Hayes +20 more
TL;DR: Comprehensive recommendations on preanalytical and analytical assessment, and interpretation and scoring of Ki67 were formulated based on current evidence, geared toward achieving a harmonized methodology, create greater between-laboratory and between-study comparability, and allow earlier valid applications of this marker in clinical practice.
Journal ArticleDOI
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Jack Cuzick,Ivana Sestak,Michael Baum,Aman U. Buzdar,Anthony Howell,Mitch Dowsett,John F. Forbes +6 more
TL;DR: The Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial as discussed by the authors was designed to compare the efficacy and safety of anastrozole (1 mg) with tamioxifen (20 mg) as adjuvant treatment for postmenopausal women with early stage breast cancer.
Journal ArticleDOI
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain,William E. Barlow,Steven Shak,Gabriel N. Hortobagyi,Robert B. Livingston,I-Tien Yeh,Peter M. Ravdin,Roberto Bugarini,Frederick L. Baehner,Nancy E. Davidson,George W. Sledge,Eric P. Winer,Clifford A. Hudis,James N. Ingle,Edith A. Perez,Kathleen I. Pritchard,Lois E. Shepherd,Julie Gralow,Carl Yoshizawa,D. Craig Allred,C. Kent Osborne,Daniel F. Hayes +21 more
TL;DR: The recurrence score is prognostic for tamoxifen-treated patients with positive nodes and predicts significant benefit of CAF in tumours with a high recurrence scores, as well as overall survival and breast-cancer-specific survival.
Journal ArticleDOI
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,
Christine Desmedt,Fanny Piette,Sherene Loi,Yixin Wang,Françoise Lallemand,Benjamin Haibe-Kains,Giuseppe Viale,Mauro Delorenzi,Yi Zhang,Mahasti Saghatchian d'Assignies,Jonas Bergh,Rosette Lidereau,Paul Ellis,Adrian L. Harris,Jan Klijn,John A. Foekens,Fatima Cardoso,Martine Piccart,Marc Buyse,Christos Sotiriou +19 more
TL;DR: This independent validation confirmed the performance of the 76-gene signature and adds to the growing evidence that gene expression signatures are of clinical relevance, especially for identifying patients at high risk of early distant metastases.
Journal ArticleDOI
A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen
Xiao Jun Ma,Zuncai Wang,Paula D. Ryan,Steven J. Isakoff,Anne Barmettler,Andrew P. Fuller,Beth Muir,Gayatry Mohapatra,Ranelle C. Salunga,J. Todd Tuggle,Yen Tran,Diem Tran,Ana Tassin,Paul Amon,Wilson Wang,Wei Wang,Edward Enright,Kimberly Stecker,Eden Estepa-Sabal,Barbara L. Smith,Jerry Younger,Ulysses J. Balis,James S. Michaelson,Atul K. Bhan,Karleen Habin,Thomas M. Baer,Joan S. Brugge,Daniel A. Haber,Mark G. Erlander,Dennis C. Sgroi +29 more
TL;DR: An expression signature predictive of disease-free survival was reduced to a two-gene ratio, HOXB13 versus IL17BR, which outperformed existing biomarkers and may be useful for identifying patients appropriate for alternative therapeutic regimens in early-stage breast cancer.
Related Papers (5)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker,Michael Mullins,Maggie C.U. Cheang,Samuel Leung,David Voduc,Tammi L. Vickery,Sherri R. Davies,Christiane Fauron,Xiaping He,Zhiyuan Hu,John Quackenbush,Inge J. Stijleman,Juan P. Palazzo,James Stephen Marron,Andrew B. Nobel,Elaine R. Mardis,Torsten O. Nielsen,Matthew J. Ellis,Charles M. Perou,Philip S. Bernard +19 more
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain,William E. Barlow,Steven Shak,Gabriel N. Hortobagyi,Robert B. Livingston,I-Tien Yeh,Peter M. Ravdin,Roberto Bugarini,Frederick L. Baehner,Nancy E. Davidson,George W. Sledge,Eric P. Winer,Clifford A. Hudis,James N. Ingle,Edith A. Perez,Kathleen I. Pritchard,Lois E. Shepherd,Julie Gralow,Carl Yoshizawa,D. Craig Allred,C. Kent Osborne,Daniel F. Hayes +21 more
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
C Davies,Hongchao Pan,Jon Godwin,Richard Gray,Rodrigo Arriagada,Vinod Raina,Mirta Abraham,Victor Hugo Medeiros Alencar,Atef Badran,Xavier Bonfill,Joan Caroline Bradbury,Mike Clarke,Rory Collins,Susan R. Davis,Antonella Delmestri,John F. Forbes,Peiman Haddad,Ming-Feng Hou,Moshe Inbar,Hussein M. Khaled,Joanna Kielanowska,Wing-Hong Kwan,Beela Sarah Mathew,Indraneel Mittra,Bettina Muller,Antonio Nicolucci,Octavio Peralta,Fany Pernas,Lubos Petruzelka,Tadeusz Pienkowski,Ramachandran Radhika,Balakrishnan Rajan,Maryna Rubach,Sera Tort,Gerard Urrútia,Miriam Valentini,Yaochen Wang,Richard Peto +37 more